Phase II trial with oral XXXX in @entity0 .

@entity1 @entity1665 @entity0 @entity882 @entity4349 @entity5699 @entity8779 @entity294 @entity1431 @entity1370 @entity1209
@entity8779 , a new analogue of @entity5699 , was administered to 27 @entity1 with @entity0 in a phase II trial. The drug was given orally at a dose of 30-35 mg/m2 every 3 weeks. Twenty-two @entity1 were evaluable for response. All evaluable @entity1 were previously treated with one or more chemotherapeutic regimens, including an @entity4349 in more than 50% of the cases. Partial remissions were obtained in 5 @entity1 , for a response rate of 23%. The median duration of response was 191 days. Mild @entity1209 were common. @entity294 , which occurred in less than 50% of the @entity1 , was usually short-lived. @entity1665 was generally minimal. Myelosuppression was the dose-limiting toxic effect. @entity1431 was frequently seen, with full recovery by day 28 in 81% of the courses. @entity882 was less common than @entity1431 . Four cases of grade 1 @entity1370 were recorded. This study suggests that @entity8779 can induce regressions in advanced @entity0 , and justifies further studies in combination with other agents.
